|
Current issue
Archive
Videos
Articles in press
About the journal
Supplements
Editorial board
Reviewers
Abstracting and indexing
Subscription
Contact
Instructions for authors
Publication charge
Ethical standards and procedures
Editorial System
Submit your Manuscript
|
1/2010
vol. 112 abstract:
Case report
Use of bevacizumab as an additional strategy in angle closure glaucoma – case report
Iwona Helemejko
1
,
Joanna Jurowska-Liput
1
Online publish date: 2010/03/21
View
full text
Get citation
ENW EndNote
BIB JabRef, Mendeley
RIS Papers, Reference Manager, RefWorks, Zotero
AMA
APA
Chicago
Harvard
MLA
Vancouver
We report the use of bevacizumab (Avastin) as an additional strategy in angle closure glaucoma based on the case of 47 years old male qualified to cataract removal as anti-glaucoma procedure, in whom we observed iris and lens neovascularization. As a first step we administered 1.25 mg of bevacizumab into the anterior chamber. Iris as well as lens neovasularization completely disappeared after 48 hours later. Finally after lens removal we achieved deeper anterior chamber, reduction and stabilization of intraocular pressure without necessity of administration hipotensive agents, and improvement of visual acuity.
keywords:
angle closure glaucoma, bevacizumab, iris neovascularization, shallow anterior chamber |
|
POLSKI
